| CAS NO: | 162831-31-4 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 412.25 |
|---|---|
| Formula | C16H30N2.2HBr |
| CAS No. | 162831-31-4 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 82 mg/mL (198.9 mM) |
| Water: 82 mg/mL (198.9 mM) | |
| Ethanol: <1 mg/mL | |
| Solubility (In vivo) | 30% propylene glycol, 5% Tween 80, 65% D5W: 30 mg/mL |
| Synonyms | IEM-1754; IEM-1754 dihydrobromide; IEM 1754; IEM1754; IEM1754 dihydrobromide; IEM-1754 2HBr; IEM 1754 dihydrobromide; IEM 1754 2HBr; IEM1754 2HBr |
| In Vitro | In vitro activity: IEM 1754 is an adamantane derivative. IEM 1754 causes use- and voltage-dependent block of open channels of recombinant AMPA receptors. This antagonism is dependent on receptor subunit composition, channels gated by recombinant, homomeric GluR1 and GluR3 receptors exhibites a higher sensitivity to block than those gated by receptors containing edited GluR2 subunits. IEM-1754 block of GluR2-containing AMPAR is enhanced by hyperpolarization in agreement with the classical single-exponential model. In contrast, the block of GluR2-lacking AMPAR is reduced by hyperpolarization |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | J Physiol. 1997 Dec 15;505 ( Pt 3):655-63; Br J Pharmacol. 2000 Jan;129(2):265-74. |
m.cnreagent.com